#United States #Chicago #Cenobamate #SK Life Science #Epilepsy

SK Life Science to Present New Data at AAN Annual Meeting 2026

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co. Ltd, is set to make significant contributions at the American Academy of Neurology (AAN) Annual Meeting, scheduled from April 18 to 22, 2026 in Chicago, Illinois. Their presentations promise to illuminate fresh insights into the management and communication strategies surrounding epilepsy treatments, particularly focusing on their innovative medication, cenobamate.

Overview of Presentations

During the conference, SK Life Science will showcase a series of poster presentations that dig deep into various dimensions of epilepsy care and treatment. These encompass both clinical trial outcomes and real-world evidence, aiming to enhance understanding of how cenobamate can impact the lives of those struggling with epilepsy. Through these findings, healthcare providers and researchers alike will glean valuable insights on potential improvements in patient care and treatment efficacy.

Key Fascinators from the Presentations

Some of the standout studies to be presented include:

• - Healthcare Utilization: This poster analyzes the healthcare resource use for epilepsy patients after they start adjunctive cenobamate treatment.
• - Seizure Outcomes: It assesses how achieving zero seizures can influence healthcare utilization among patients.
• - Clinical Efficacy and Safety: Presentations will also cover practical findings related to safety and efficacy in both adults and adolescents having primary generalized tonic-clonic seizures.
• - Pharmacokinetics: Researchers will provide analyses on drug exposure in differing patient demographics, including elderly patients with focal seizures.
• - Long-term Data: The presentations will also deliver results from open-label extensions concerning cenobamate's long-term efficacy across multinational patient cohorts.

The Hope, Hesitancy, and Hard Truths Survey

An exciting element of SK Life Science’s contribution will be a detailed methodological analysis stemming from their Hope, Hesitancy, and Hard Truths survey. This initiative has been critical in evaluating the communication dynamics between epilepsy patients and their healthcare providers.
By engaging a diverse group of participants—including patients living with epilepsy and various healthcare specialists—this survey has provided rich qualitative data highlighting what barriers exist in treatment discussions. Initial findings from this comprehensive survey were shared during the National Epilepsy Awareness Month in November 2025, emphasizing the essential links between patient expectations, communications, and treatment outcomes.

Dr. Sunita Misra, the Chief Medical Officer at SK Life Science, emphasized the importance of understanding the communication gaps that currently hinder optimal care. As she articulated, “Bringing together the patient’s voice with those of healthcare providers is essential in bridging treatment gaps.” By bringing forward these collective experiences, SK Life Science aims to catalyze conversations that address the hesitancies patients often face in managing their treatment.

Epilepsy: An Overview

Epilepsy remains a pressing public health concern. In the U.S. alone, there are approximately 3.4 million individuals living with this disorder, with around 150,000 new cases diagnosed each year. Despite the treatments on offer, nearly 40% of people with epilepsy do not achieve seizure freedom, impacting their quality of life substantially. This makes research and innovations in treatment, like those presented by SK Life Science, of paramount importance.

As the world gathers at the AAN 2026, the anticipated contributions by SK Life Science not only promise to enhance understanding of cenobamate’s role in epilepsy management but also serve to spotlight the critical aspects of patient-provider communication necessary for effective management of this complex neurological condition. Through these presentations, SK Life Science aims to enhance the landscape of epilepsy treatment and advocate for innovative approaches that directly address the needs of patients.

With so much riding on effective communication and collaboration in treatment, the presentations at AAN 2026 are set to deliver crucial insights that could reshape the future of epilepsy care for countless individuals.